DAT-230, a novel microtubule inhibitor, exhibits potent anti-tumor activity by inducing G2/M phase arrest, apoptosis in vitro and perfusion decrease in vivo to HT-1080

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 2, 2012, Pages 259-270

  Qiao, Foxiao ^a   Zuo, Daiying ^a   Shen, Xueqi ^a   Qi, Huan ^a   Wang, Haifeng ^a   Zhang, Weige ^a   Wu, Yingliang ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Anti tumor activity; Apoptosis; Cell cycle arrest; Fibrosarcoma; Microtubule inhibitor

Indexed keywords

2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)THIOPHEN 3 YL]ANILINE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 9; CYCLIN B1; CYCLIN DEPENDENT KINASE 1; DAT 230; HOE 33342; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE; PROTEIN BAX; PROTEIN BCL 2; THREONINE; THREONINE 14; THYROSINE 15; THYROXINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; FEMALE; FIBROBLAST; FIBROSARCOMA; FLOW CYTOMETRY; FLUORESCENCE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE ASSEMBLY; MICROTUBULE DEPOLYMERIZATION; MICROTUBULE ORGANIZING CENTER; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PERFUSION; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TOXICITY TESTING; TUMOR GROWTH; TUMOR PERFUSION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; FIBROSARCOMA; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MOLECULAR STRUCTURE; NITRIC OXIDE; REACTIVE OXYGEN SPECIES; THIOPHENES; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866526294     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1907-x     Document Type: Article

References (44)

1. Wu R, Ding W, Liu T, Zhu H, Hu Y, Yang B, He Q (2009) XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro. Cancer Lett 285(1):13-22
2. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ (1991) Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer 27(4):482-487
3. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ (1993) Vinca alkaloids: Anti-vascular effects in a murine tumour. Eur J Cancer 29A(9):1320-1324
4. Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T, Saito S, Hori K, Sato Y (1999) Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 90(12):1387-1395
5. Woods JA, Hadfield JA, Pettit GR, Fox BW, McGown AT (1995) The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer 71(4):705-711
6. Grosios K, Holwell SE, Mc AT, Pettit GR, Bibby MC (1999) In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 81(8):1318-1327
7. Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 8(6):1974-1983
8. Griggs J, Metcalfe JC, Hesketh R (2001) Targeting tumour vasculature: The development of combretastatin A4. Lancet Oncol 2(2):82-87
9. Chaplin DJ, Dougherty GJ (1999) Tumour vasculature as a target for cancer therapy. Br J Cancer 80(Suppl 1):57-64
10. Otani M, Natsume T, Watanabe JI, Kobayashi M, Murakoshi M, Mikami T, Nakayama T (2000) TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 91(8):837-844
11. Nam NH (2003) Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Med Chem 10(17):1697-1722
12. Kanthou C, Tozer GM (2009) Microtubule depolymerizing vascular disrupting agents: Novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 90(3):284-294
13. Marrelli M, Conforti F, Statti GA, Cachet X, Michel S, Tillequin F, Menichini F (2011) Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: An overview of new derivatives of natural combretastatin a-4. Curr Med Chem 18(20):3035-3081
14. Liou JP, Hsu KS, Kuo CC, Chang CY, Chang JY (2007) A novel oral indoline-sulfonamide agent, N-[1-(4-methoxybenzenesulfonyl)-2,3-dihydro-1H- indol-7-yl]-isonicotinamide (J30), exhibits potent activity against human cancer cells in vitro and in vivo through the disruption of microtubule. J Pharmacol Exp Ther 323(1):398-405
15. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L (1995) Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 55(20):4623-4626
16. Zhu H, Zhang J, Xue N, Hu Y, Yang B, He Q (2010) Novel combretastatin A-4 derivative XN0502 induces cell cycle arrest and apoptosis in A549 cells. Invest New Drugs 28(4):493-501
17. Saris NE, Teplova VV, Odinokova IV, Azarashvily TS (2004) Interference of calmidazolium with measurement of mitochondrial membrane potential using the tetraphenylphosphonium electrode or the fluorescent probe rhodamine 123. Anal Biochem 328(2):109-112
18. Mikirova NA, Ichim TE, Riordan NH (2008) Anti-angiogenic effect of high doses of ascorbic acid. J Transl Med 6:50. doi: 1479-5876-6-50
19. Dalal S, Burchill SA (2009) Preclinical evaluation of vasculardisrupting agents in Ewing's sarcoma family of tumours. Eur J Cancer 45(4):713-722
20. Homesley HD, Filiaci V, Gibbons SK, Long HJ, Cella D, Spirtos NM, Morris RT, DeGeest K, Lee R, Montag A (2009) A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study. Gynecol Oncol 112(3):543-552
21. King KL, Cidlowski JA (1995) Cell cycle and apoptosis: Common pathways to life and death. J Cell Biochem 58(2):175-180
22. Toyoshima F, Moriguchi T, Wada A, Fukuda M, Nishida E (1998) Nuclear export of cyclin B1 and its possible role in the DNA damage-induced G2 checkpoint. EMBO J 17(10):2728-2735
23. Meijer L, Azzi L, Wang JY (1991) Cyclin B targets p34cdc2 for tyrosine phosphorylation. EMBO J 10(6):1545-1554
24. Suen DF, Norris KL, Youle RJ (2008) Mitochondrial dynamics and apoptosis. Genes Dev 22(12):1577-1590
25. Smith KA, Hill SA, Begg AC, Denekamp J (1988) Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumours. Br J Cancer 57(3):247-253
26. Papagelopoulos PJ, Galanis EC, Trantafyllidis P, Boscainos PJ, Sim FH, Unni KK (2002) Clinicopathologic features, diagnosis, and treatment of fibrosarcoma of bone. Am J Orthop (Belle Mead NJ) 31(5):253-257
27. Collin CF, Friedrich C, Godbold J, Hajdu S, Brennan MF (1988) Prognostic factors for local recurrence and survival in patients with localized extremity soft-tissue sarcoma. Semin Surg Oncol 4(1):30-37
28. Weitz J, Antonescu CR, Brennan MF (2003) Localized extremity soft tissue sarcoma: Improved knowledge with unchanged survival over time. J Clin Oncol 21(14):2719-2725
29. Cenciarelli C, Tanzarella C, Vitale I, Pisano C, Crateri P, Meschini S, Arancia G, Antoccia A (2008) The tubulin-depolymerising agent combretastatin-4 induces ectopic aster assembly and mitotic catastrophe in lung cancer cells H460. Apoptosis 13(5): 659-669
30. Doree M, Galas S (1994) The cyclin-dependent protein kinases and the control of cell division. FASEB J 8(14):1114-1121
31. Porter LA, Donoghue DJ (2003) Cyclin B1 and CDK1: Nuclear localization and upstream regulators. Prog Cell Cycle Res 5:335-347
32. Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, Al-Katib AM(2002) Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADPribose) polymerase cleavage. Clin Cancer Res 8(8):2735-2741
33. Nicholson DW (2000) From bench to clinic with apoptosis-based therapeutic agents. Nature 407(6805):810-816
34. Desagher S, Martinou JC (2000) Mitochondria as the central control point of apoptosis. Trends Cell Biol 10(9):369-377
35. Ryan L, O'Callaghan YC, O'Brien NM (2005) The role of the mitochondria in apoptosis induced by 7beta-hydroxycholesterol and cholesterol-5beta,6beta- epoxide. Br J Nutr 94(4):519-525
36. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T (1996) Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 334(24):1561-1567
37. Holmes WF, Soprano DR, Soprano KJ (2003) Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: Activation of the p38 MAP kinase signal pathway. Oncogene 22:6377-6386
38. Mendez G, Policarpi C, Cenciarelli C, Tanzarella C, Antoccia A (2011) Role of Bim in apoptosis induced in H460 lung tumor cells by the spindle poison Combretastatin-A4. Apoptosis 16:940-949
39. Mollinedo F, Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8:413-450
40. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57(10): 1829-1834
41. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ (1999) Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res 59(7):1626-1634
42. Siemann DW, Chaplin DJ, Walicke PA (2009) A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA-4P). Expert Opin Investig Drugs 18(2):189-197
43. Wehbe H, Kearney CM, Pinney KG (2005) Combretastatin A-4 resistance in H460 human lung carcinoma demonstrates distinctive alterations in beta-tubulin isotype expression. Anticancer Res 25:3865-3870
44. Quan H, Liu H, Li C, Lou L (2009) 1,4-Diamino-2,3-dicyano-1,4-bis (methylthio) butadiene (U0126) enhances the cytotoxicity of combretastatin A4 independently of mitogen-activated protein kinase kinase. J Pharmacol Exp Ther 330:326-333